Eli Lilly Returns to Vaccine Business with $3.8 Billion Deal

Eli Lilly & Co. is acquiring three clinical-stage vaccine developers for up to $3.8 billion in total, aiming to become a leader in infectious diseases. This move is seen as part of the company's strategy to channel cash from obesity drugs into other disease areas. According to Bloomberg, Lilly's re-entry into the vaccine business through these acquisitions reflects efforts to diversify its portfolio and invest in high-growth potential areas. The company had previously operated in the vaccine space but later withdrew. Under the deal, Lilly will incorporate the vaccine candidates and related technologies of three different companies, which are intended to provide protection against respiratory infections and other infectious diseases. This investment could increase competition in the global vaccine market and strengthen Lilly's R&D portfolio. However, the completion of the deal and regulatory approvals may take several months. This is not investment advice.